… for lung diseases. AIM: In this review, we aimed to investigate the effects of diabetes and
hypoglycemic agent on lung diseases, … However, the clinical significance is unknown, mostly be…

… lung diseases such as COPD, … clinical use for lung diseases, and PFD may have potential
in this context. PFD inhibited neutrophil numbers in a bleomycin-induced mouse model of lung …

… lung aging is associated with molecular and physiological changes that cause alterations
in lung … increased susceptibility to acute and chronic lung diseases. As the aging population …

… lung disease, being detected in up to 60% of patients with RA on high-resolution computed
tomography (HRCT), clinically significant … Onset of lung disease typically occurs in the fifth to …

… lung disease is the most common cause of death among patients with systemic sclerosis,
with a prevalence of up to 30% and a 10-year mortality of up to 40%. Interstitial lung disease is …

… Until 2019, a role for antifibrotic therapy in the treatment of other fibrotic lung diseases had
… at the third International Summit for Interstitial Lung Diseases. An expert consensus on key …

… A proportion of patients with certain types of interstitial lung disease (ILD), including chronic
… diseases, develop a progressive fibrosing phenotype that shows similarities in clinical …

… The lifetime risk of developing clinically significant ILD in patients with RA is estimated to be
10… RA-ILD has a variable clinical course but may result in severe impairment in lung function […

… should be considered when there is clinically significant disease at presentation or evidence
of disease progression, as measured by a decline in lung function, progression of fibrosis …

… lung disease (CLD), with the main focus being on chronic obstructive pulmonary disease
(COPD) and interstitial lung disease (… ), the presence of minor lung disease affects survival [6]. …